Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + napabucasin
- Development stage
- Phase 2
- Lead developer
- Sumitomo Pharma America
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Capecitabine + napabucasin is an investigational combination therapy for cancer. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), a nucleoside metabolic inhibitor that interferes with DNA synthesis and inhibits tumor cell proliferation. Napabucasin (also known as BBI-608) is an orally administered small molecule hypothesized to inhibit multiple oncogenic pathways by targeting cancer stemness pathways, including the STAT3 pathway. Napabucasin increases reactive oxygen species (ROS) in cancer cells beyond cytotoxic thresholds, leading to cell death. This combination has been explored in clinical trials for advanced or metastatic gastrointestinal cancers such as pancreatic and colorectal cancers[1][4][8][9].
02
Targets
STAT3 (Signal Transducer and Activator of Transcription 3)TS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + napabucasin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + napabucasin.